Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
PaxMedica Inc
PXMD
Healthcare
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral...
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (PINL:PXMD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 2:46pm
Paxmedica, Inc. (PXMD): A Promising Biopharmaceutical Compan
https://beyondspx.com/2024/08/03/paxmedica-inc-pxmd-a-promising-biopharmaceutical-company-navigating-challenges/
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 06, 2023 9:12am
New Press Release - PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 /PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman and CEO.Overview:In this comprehensive company...
read article.
(75)
•••
Steve33
X
Post by
Steve33
on Dec 05, 2023 11:00am
PP
Imagine if you pay 1.30 for the placement then one week later it's 75 cents. All because an algorithm or shorters. BS.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 29, 2023 3:56pm
PXMD .....Anyone for a game of Spearcatching?
Post RS & Post P.O....cheaper than a large slurpee ; )
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 22, 2023 4:10pm
New Press Release - PaxMedica Announces Closing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the closing of its previously announced public offering of an aggregate of 5,384...
read article.
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Nov 20, 2023 9:31am
RE:PXMD....NR this a.m....Fluff promo ; )
NR this a.m on P.O pricing.....Told ya ; ) Cheers !
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 20, 2023 9:18am
New Press Release - PaxMedica Announces Pricing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 /PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 17, 2023 8:25am
PXMD....NR this a.m....Fluff promo ; )
Just waiting for the P.O to be announced JMHO
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 17, 2023 8:00am
New Press Release - PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 15, 2023 6:52pm
New Press Release - PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 15, 2023 10:31am
PXMD .... Only Bagholders and FOMO's left in this ; )
Waiting for the P.O announcement Cheers
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 14, 2023 11:01am
PXMD....huge scalp...Cha Ching!!!!
Now lets have the P.O announcement....S1 filed and waiting ; )
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 14, 2023 10:23am
PXMD ...may have found the bottom yesterday ; )
Nice volume increase and price action this a.m On watch and no position
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Nov 07, 2023 2:50pm
RE:PXMD ....Halt #5 still in PB mode & filling gaps
Looks like I was correct....gap # 3 getting filled Wheres the bottom u ask...don't ask me ; )
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 07, 2023 12:26pm
PXMD ....start the drumroll
will this implode now???? $5.60
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities